IL-12-armed oncolytic HSV-2 enhances CAR T cell efficacy against pancreatic cancer in xenografted models
This synergistic approach achieves durable potent tumor clearance with reduced CAR-T doses, offering a transformative strategy against pancreatic cancer and other challenging solid malignancies.
Authors
- Chunyi Tu (ORCID: https://orcid.org/0000-0001-7755-1861)
- Binlei Liu (ORCID: https://orcid.org/0000-0002-2852-600X)
- Shufang Meng (ORCID: https://orcid.org/0009-0001-9535-2660)
- Yanliang Liu (ORCID: https://orcid.org/0000-0002-9815-4416)
- Qian Liang
- Xiaoya Zhou
- Zilong Tang
- Chongfeng Xu
- Han Hu
- Jian Wu
- Qiying Cai
- Guoya Li
- Yang Wang
- Weikang Liu
Institutions
- National Medical Products Administration (CN)
- Ministero della Salute (IT)
- Centre for Innovation in Regulatory Science (GB)
- Wuhan Institute of Bioengineering (CN)
- Zoucheng People's Hospital (CN)
- National Institutes for Food and Drug Control (CN)
- Hubei University of Technology (CN)
- Hubei University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-16
- DOI
- https://doi.org/10.3389/fimmu.2025.1664289
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes for Food and Drug Control